Stock CPRX CATALYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
15.54 USD +0.97% Intraday chart for Catalyst Pharmaceuticals, Inc. -1.58% -7.56%
Apr. 10 Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing MT
Apr. 04 Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing
MT
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.
CI
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.
CI
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.
CI
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing
MT
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
GL
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
GL
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target
MT
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States
DJ
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy
MT
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
GL
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
AQ
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy
CI
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals
MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23
MT
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
GL
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
AQ
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating
MT
Transcript : Catalyst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 29, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CPRX Stock
  4. News Catalyst Pharmaceuticals, Inc.